Related Experiment Videos
Adjuvant therapy of colon cancer: lessons while looking for breakthroughs
1Department of Medicine, Kenneth Norris Jr Comprehensive Cancer Center, University of Southern California, Los Angeles.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
Gynecologic oncology·2024
National Outcomes of Liver Transplantation for Model for End-Stage Liver Disease Score ≥40: The Impact of Share 35.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.
Prostate cancer and prostatic diseases·2014
BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
Annals of oncology : official journal of the European Society for Medical Oncology·2013
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.
Annals of oncology : official journal of the European Society for Medical Oncology·2026